Identification

Name
Neomycin
Accession Number
DB00994  (APRD00013)
Type
Small Molecule
Groups
Approved, Vet Approved
Description

A component of neomycin that is produced by Streptomyces fradiae. On hydrolysis it yields neamine and neobiosamine B. (From Merck Index, 11th ed). Neomycin is a bactericidal aminoglycoside antibiotic that binds to the 30S ribosome of susceptible organisms. Binding interferes with mRNA binding and acceptor tRNA sites and results in the production of non-functional or toxic peptides.

Structure
Thumb
Synonyms
Not Available
External IDs
Caswell No. 595 / USAF CB-19
Product Ingredients
IngredientUNIICASInChI Key
Neomycin palmitate3I9J454G9F55298-68-5Not applicable
Neomycin sulfate88L7V8H11U1215860-56-2OIXVKQDWLFHVGR-CITJEJKVSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Mycifradin Sulfate Oral SolutionSolution125 mgOralPharmacia & Upjohn Inc1957-12-312000-08-02Canada
Mycifradin Sulfate Tablets 0.5 GmTablet500 mgOralPharmacia & Upjohn Inc1953-12-312000-08-02Canada
Myciguent OintmentOintment.5 %TopicalUpjohn1951-12-311998-08-12Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Neo-FradinSolution87.5 mg/5mLOralX Gen Pharmaceuticals, Inc.2002-05-232017-01-18Us
Neomycin SulfateTablet350 mg/1OralBreckenridge Pharmaceutical, Inc.2011-01-03Not applicableUs
Neomycin SulfateTablet500 mg/1OralTeva1990-09-30Not applicableUs00093 1177 01 nlmimage10 4f2b27c9
Neomycin SulfateTablet500 mg/1OralEci Pharmaceuticals Llc2016-01-162016-10-13Us
Neomycin SulfateTablet500 mg/1OralMajor2009-09-14Not applicableUs
Neomycin SulfateTablet500 mg/1OralHi Tech Pharmacal Co., Inc.2010-03-12Not applicableUs50383 0565 10 nlmimage10 1f460f80
Neomycin SulfateTablet500 mg/1OralLannett Company, Inc.2016-06-10Not applicableUs
Neomycin SulfateTablet500 mg/1OralX Gen Pharmaceuticals, Inc.2010-03-12Not applicableUs
Neomycin SulfateTablet500 mg/1OralGolden State Medical Supply2011-01-03Not applicableUs51991 0738 01 nlmimage10 951b4ada
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AntibioticOintment3.5 mg/gTopicalMorales Distributors, Inc.2012-09-25Not applicableUs
AntibioticOintment3.5 mg/gTopicalKareway Product, Inc.2011-08-11Not applicableUs
AntibioticOintment3.5 mg/gTopicalPro Mex Llc2013-12-05Not applicableUs
Antibiotic OintmentOintment3.5 mg/gTopicalNeopharm Co., Ltd2010-08-26Not applicableUs
BaclezeneCream5 mg/.9gTopicalCurazene, Llc2014-06-19Not applicableUs
Family Care AntibioticOintment3.5 mg/gTopicalUnited Exchange Corporation2012-11-30Not applicableUs
Family Care Triple Antibiotic Pain ReliefOintment3.5 mg/gTopicalUnited Exchange Corporation2012-02-07Not applicableUs
Pomada de SulfaOintment3.5 mg/57gTopicalMenper Distributors2012-02-21Not applicableUs
Single Antibiotic with NeomycinOintment3.5 mg/gTopicalSafetec Of America Inc2008-11-13Not applicableUs
VitacilinaOintment3.5 mg/gTopicalTeresa Cecena Dba Genesis2015-05-15Not applicableUs
International/Other Brands
Myacyne / Mycifradin / Myciguent / Neo-Rx / Neobiotic / Nivemycin
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
10 Person ANSINeomycin sulfate + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Lidocaine + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-24Not applicableUs
25 Person ANSINeomycin sulfate + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Isopropyl Alcohol + Lidocaine + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-04-25Not applicableUs
50 Person ANSINeomycin sulfate + Acetaminophen + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Ibuprofen + Isopropyl Alcohol + Lidocaine + Polymyxin B Sulfate + WaterKitGenuine First Aid2010-06-02Not applicableUs
7 Select First Aid Triple AntibioticNeomycin sulfate (3.5 mg/g) + Bacitracin zinc (400 [iU]/g) + Polymyxin B Sulfate (5000 [iU]/g)OintmentTopical7 Eleven2016-12-08Not applicableUs
ACME FIRST AID Contains 404 PIECESNeomycin sulfate + Acetylsalicylic acid + Bacitracin zinc + Benzalkonium chloride + Benzocaine + Ethanol + Isopropyl Alcohol + Lidocaine + Polymyxin B Sulfate + WaterKitAcme United Corporation2010-04-27Not applicableUs
ACME Small Cuts and BurnsNeomycin sulfate + Bacitracin zinc + Benzalkonium chloride + Lidocaine + Polymyxin B SulfateKitAcme United Corporation2010-04-30Not applicableUs
AerosootheNeomycin sulfate (5 mg/g) + Bacitracin zinc (400 [iU]/g) + Polymyxin B Sulfate (5000 [iU]/g)OintmentTopicalAero Healthcare2015-10-20Not applicableUs
Aftate Triple AntibioticNeomycin sulfate (3.5 mg/g) + Bacitracin zinc (400 [iU]/g) + Polymyxin B Sulfate (5000 [iU]/g)OintmentTopicalSabel Med Llc2016-05-01Not applicableUs
American Red Cross First Aid KitNeomycin sulfate + Bacitracin zinc + Benzalkonium chloride + Ethanol + Ethanol + Polymyxin B SulfateKitTomy International2012-01-17Not applicableUs
Aminoderm PoudreNeomycin sulfate (5 mg) + Glycine (10 mg) + L-Cysteine (2 mg) + L-Threonine (1 mg)PowderTopicalDesbergers LtÉe, Division Of Technilab Inc.1968-12-312004-08-09Canada
Categories
UNII
I16QD7X297
CAS number
1404-04-2
Weight
Not Available
Chemical Formula
Not Available
InChI Key
Not Available
InChI
Not Available
IUPAC Name
Not Available
SMILES
Not Available

Pharmacology

Indication

Topical uses include treatment for superficial eye infections caused by susceptible bacteria (used in combination with other antiinfectives), treatment of otitis externa caused by susceptible bacteria, treatment or prevention of bacterial infections in skin lesions, and use as a continuous short-term irrigant or rinse to prevent bacteriuria and gram negative rod bacteremia in abacteriuric patients with indwelling catheters. May be used orally to treat hepatic encephalopathy, as a perioperative prophylactic agent, and as an adjunct to fluid and electrolyte replacement in the treatment of diarrhea caused to enteropathogenic E. coli (EPEC).

Structured Indications
Pharmacodynamics

Neomycin is an aminoglycoside antibiotic. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses.

Mechanism of action

Aminoglycosides like neomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically neomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes.

TargetActionsOrganism
A30S ribosomal protein S12
inhibitor
Escherichia coli (strain K12)
A16S rRNA
inhibitor
Enteric bacteria and other eubacteria
UExtracellular calcium-sensing receptorNot AvailableHuman
Absorption

Poorly absorbed from the normal gastrointestinal tract. Although only approximately 3% of neomycin is absorbed through intact intestinal mucosa, significant amounts may be absorbed through ulcerated or denuded mucosa or if inflammation is present.

Volume of distribution
Not Available
Protein binding

Protein binding studies have shown that the degree of aminoglycoside protein binding is low and, depending upon the methods used for testing, may be between 0% and 30%.

Metabolism

Neomycin undergoes negligible biotransformation after parenteral administration.

Route of elimination

The small absorbed fraction is rapidly distributed in the tissues and is excreted by the kidney in keeping with the degree of kidney function.

Half life

2 to 3 hours

Clearance
Not Available
Toxicity

LD50 = 200 mg/kg (rat). Because of low absorption, it is unlikely that acute overdosage would occur with oral neomycin. However, prolonged administration could result in sufficient systemic drug levels to produce neurotoxicity, ototoxicity and/or nephrotoxicity. Nephrotoxicity occurs via drug accumulation in renal proximal tubular cells resulting in cellular damage. Tubular cells may regenerate despite continued exposure and nephrotoxicity is usually mild reversible. Neomycin is the most toxic aminoglycoside agent, which is thought to be due to its large number of cationic amino groups. Otoxocity occurs via drug accumulation in the endolymph and perilymph of the inner ear causing irreversible damage to hair cells in the cochlea or summit of ampullar cristae in the vestibular complex. High frequency hearing loss is followed by low frequency hearing loss. Further toxicity may cause retrograde degeneration of the auditory nerve. Vestibular toxicity may result in vertigo, nausea and vomiting, dizziness and loss of balance.

Affected organisms
  • Enteric bacteria and other eubacteria
  • Escherichia coli
  • Klebsiella
  • Enterobacter
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AcarboseThe risk or severity of adverse effects can be increased when Neomycin is combined with Acarbose.Approved, Investigational
AceclofenacAceclofenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
AcemetacinAcemetacin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
AcenocoumarolNeomycin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be decreased when it is combined with Neomycin.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be decreased when it is combined with Neomycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
AdapaleneAdapalene may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
AlclofenacAlclofenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumNeomycin may increase the respiratory depressant activities of Alcuronium.Experimental
Alendronic acidNeomycin may increase the hypocalcemic activities of Alendronic acid.Approved
AlminoprofenAlminoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
AmdinocillinThe serum concentration of Neomycin can be decreased when it is combined with Amdinocillin.Withdrawn
AmoxicillinThe serum concentration of Neomycin can be decreased when it is combined with Amoxicillin.Approved, Vet Approved
Amphotericin BAmphotericin B may increase the nephrotoxic activities of Neomycin.Approved, Investigational
AmpicillinThe serum concentration of Neomycin can be decreased when it is combined with Ampicillin.Approved, Vet Approved
AndrographolideAndrographolide may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
AnisodamineAnisodamine may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
ApocyninApocynin may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
ApremilastApremilast may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
AspoxicillinThe serum concentration of Neomycin can be decreased when it is combined with Aspoxicillin.Experimental
AtracuriumNeomycin may increase the respiratory depressant activities of Atracurium.Experimental
Atracurium besylateNeomycin may increase the respiratory depressant activities of Atracurium besylate.Approved
AzapropazoneAzapropazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
AzelastineAzelastine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
AzidocillinThe serum concentration of Neomycin can be decreased when it is combined with Azidocillin.Approved
AzlocillinThe serum concentration of Neomycin can be decreased when it is combined with Azlocillin.Approved
BacampicillinThe serum concentration of Neomycin can be decreased when it is combined with Bacampicillin.Approved
BacitracinNeomycin may increase the nephrotoxic activities of Bacitracin.Approved, Vet Approved
BalsalazideBalsalazide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Neomycin.Investigational
BendazacBendazac may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
BenorilateBenorilate may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
Benzathine benzylpenicillinThe serum concentration of Neomycin can be decreased when it is combined with Benzathine benzylpenicillin.Approved, Vet Approved
BenzylpenicillinThe serum concentration of Neomycin can be decreased when it is combined with Benzylpenicillin.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of Neomycin can be decreased when it is combined with Benzylpenicilloyl Polylysine.Approved
BevoniumBevonium may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
Botulinum Toxin Type ANeomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BNeomycin may increase the neuromuscular blocking activities of Botulinum Toxin Type B.Approved
BromfenacBromfenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
BucillamineBucillamine may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
BufexamacBufexamac may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
BumadizoneBumadizone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Neomycin.Approved
CapreomycinCapreomycin may increase the neuromuscular blocking activities of Neomycin.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
CarbenicillinThe serum concentration of Neomycin can be decreased when it is combined with Carbenicillin.Approved
Carbenicillin indanylThe serum concentration of Neomycin can be decreased when it is combined with Carbenicillin indanyl.Approved
CarboplatinNeomycin may increase the ototoxic activities of Carboplatin.Approved
CarfecillinThe serum concentration of Neomycin can be decreased when it is combined with Carfecillin.Experimental
CarprofenCarprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
CelecoxibCelecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
ChloroquineChloroquine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
CisatracuriumNeomycin may increase the respiratory depressant activities of Cisatracurium.Experimental
Cisatracurium besylateNeomycin may increase the respiratory depressant activities of Cisatracurium besylate.Approved
CisplatinCisplatin may increase the nephrotoxic activities of Neomycin.Approved
Clodronic AcidNeomycin may increase the hypocalcemic activities of Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinClonixin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
ClorindioneNeomycin may increase the anticoagulant activities of Clorindione.Experimental
CloxacillinThe serum concentration of Neomycin can be decreased when it is combined with Cloxacillin.Approved, Vet Approved
ColistimethateNeomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
CurcuminCurcumin may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
CyclacillinThe serum concentration of Neomycin can be decreased when it is combined with Cyclacillin.Approved
CyclosporineNeomycin may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be decreased when it is combined with Neomycin.Experimental
D-LimoneneD-Limonene may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
DecamethoniumNeomycin may increase the respiratory depressant activities of Decamethonium.Approved
DeslanosideThe serum concentration of Deslanoside can be decreased when it is combined with Neomycin.Approved
DiclofenacDiclofenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
DicloxacillinThe serum concentration of Neomycin can be decreased when it is combined with Dicloxacillin.Approved, Vet Approved
DicoumarolNeomycin may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideDifenpiramide may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Neomycin.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Neomycin.Approved
DiphenadioneNeomycin may increase the anticoagulant activities of Diphenadione.Experimental
Domoic AcidNeomycin may increase the respiratory depressant activities of Domoic Acid.Experimental
Doxacurium chlorideNeomycin may increase the respiratory depressant activities of Doxacurium chloride.Approved
DroxicamDroxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
DuvelisibDuvelisib may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
E-6201E-6201 may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
EpicillinThe serum concentration of Neomycin can be decreased when it is combined with Epicillin.Experimental
EpirizoleEpirizole may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Neomycin.Approved
EtanerceptEtanercept may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
EthenzamideEthenzamide may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
Ethyl biscoumacetateNeomycin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidNeomycin may increase the hypocalcemic activities of Etidronic acid.Approved
EtodolacEtodolac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
EtoricoxibEtoricoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
exisulindexisulind may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
FelbinacFelbinac may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
FenoprofenFenoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
FentiazacFentiazac may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
FeprazoneFeprazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
Ferulic acidFerulic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
FloctafenineFloctafenine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Withdrawn
FlucloxacillinThe serum concentration of Neomycin can be decreased when it is combined with Flucloxacillin.Approved
FluindioneNeomycin may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may decrease the excretion rate of Neomycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
FlurbiprofenFlurbiprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
FoscarnetFoscarnet may increase the nephrotoxic activities of Neomycin.Approved
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Neomycin.Approved, Vet Approved
GallamineNeomycin may increase the respiratory depressant activities of Gallamine.Experimental
Gallamine TriethiodideNeomycin may increase the respiratory depressant activities of Gallamine Triethiodide.Approved
GitoformateThe serum concentration of Gitoformate can be decreased when it is combined with Neomycin.Experimental
GuacetisalGuacetisal may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
HigenamineHigenamine may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
IbandronateNeomycin may increase the hypocalcemic activities of Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
IcatibantIcatibant may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
IndobufenIndobufen may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
IsoxicamIsoxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
KebuzoneKebuzone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
KetoprofenKetoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
Lanatoside CThe serum concentration of Lanatoside C can be decreased when it is combined with Neomycin.Experimental
LeflunomideLeflunomide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
LisofyllineLisofylline may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
LonazolacLonazolac may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
LornoxicamLornoxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
LumiracoxibLumiracoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
MannitolMannitol may increase the nephrotoxic activities of Neomycin.Approved, Investigational
MasoprocolMasoprocol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
MecamylamineNeomycin may increase the neuromuscular blocking activities of Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
MeloxicamMeloxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
MesalazineMesalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
MetamizoleMetamizole may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
MetampicillinThe serum concentration of Neomycin can be decreased when it is combined with Metampicillin.Experimental
MeticillinThe serum concentration of Neomycin can be decreased when it is combined with Meticillin.Approved
MetildigoxinThe serum concentration of Metildigoxin can be decreased when it is combined with Neomycin.Experimental
MetocurineNeomycin may increase the respiratory depressant activities of Metocurine.Approved
Metocurine IodideNeomycin may increase the respiratory depressant activities of Metocurine Iodide.Withdrawn
MezlocillinThe serum concentration of Neomycin can be decreased when it is combined with Mezlocillin.Approved
MivacuriumNeomycin may increase the respiratory depressant activities of Mivacurium.Approved
MizoribineMizoribine may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
NabumetoneNabumetone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
NafamostatNafamostat may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
NafcillinThe serum concentration of Neomycin can be decreased when it is combined with Nafcillin.Approved
NaftifineNaftifine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
NaproxenNaproxen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NeosaxitoxinNeomycin may increase the respiratory depressant activities of Neosaxitoxin.Investigational
NepafenacNepafenac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
NifenazoneNifenazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Withdrawn
NitroaspirinNitroaspirin may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
OleandrinThe serum concentration of Oleandrin can be decreased when it is combined with Neomycin.Experimental
OlopatadineOlopatadine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
OlsalazineOlsalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
OrgoteinOrgotein may decrease the excretion rate of Neomycin which could result in a higher serum level.Vet Approved
OuabainThe serum concentration of Ouabain can be decreased when it is combined with Neomycin.Approved
OxacillinThe serum concentration of Neomycin can be decreased when it is combined with Oxacillin.Approved
OxaprozinOxaprozin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
PamidronateNeomycin may increase the hypocalcemic activities of Pamidronate.Approved
PancuroniumNeomycin may increase the respiratory depressant activities of Pancuronium.Approved
ParecoxibParecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
ParthenolideParthenolide may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
PenamecillinThe serum concentration of Neomycin can be decreased when it is combined with Penamecillin.Experimental
PenimepicyclineThe serum concentration of Neomycin can be decreased when it is combined with Penimepicycline.Experimental
PeruvosideThe serum concentration of Peruvoside can be decreased when it is combined with Neomycin.Experimental
PhenindioneNeomycin may increase the anticoagulant activities of Phenindione.Approved
PhenoxymethylpenicillinThe serum concentration of Neomycin can be decreased when it is combined with Phenoxymethylpenicillin.Approved, Vet Approved
PhenprocoumonNeomycin may increase the anticoagulant activities of Phenprocoumon.Approved
PhenylbutazonePhenylbutazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Neomycin.Approved
PimecrolimusPimecrolimus may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
PipecuroniumNeomycin may increase the respiratory depressant activities of Pipecuronium.Approved
PiperacillinThe serum concentration of Neomycin can be decreased when it is combined with Piperacillin.Approved
PiretanideThe risk or severity of adverse effects can be increased when Piretanide is combined with Neomycin.Experimental
PirfenidonePirfenidone may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
PiroxicamPiroxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
PivampicillinThe serum concentration of Neomycin can be decreased when it is combined with Pivampicillin.Approved
PivmecillinamThe serum concentration of Neomycin can be decreased when it is combined with Pivmecillinam.Approved
PranoprofenPranoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
Procaine benzylpenicillinThe serum concentration of Neomycin can be decreased when it is combined with Procaine benzylpenicillin.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
PropacetamolPropacetamol may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
PropicillinThe serum concentration of Neomycin can be decreased when it is combined with Propicillin.Experimental
PropyphenazonePropyphenazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
ProscillaridinThe serum concentration of Proscillaridin can be decreased when it is combined with Neomycin.Experimental
PTC299PTC299 may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
PyrantelNeomycin may increase the respiratory depressant activities of Pyrantel.Approved, Vet Approved
RapacuroniumNeomycin may increase the respiratory depressant activities of Rapacuronium.Withdrawn
ResveratrolResveratrol may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental, Investigational
RisedronateNeomycin may increase the hypocalcemic activities of Risedronate.Approved, Investigational
RocuroniumNeomycin may increase the respiratory depressant activities of Rocuronium.Approved
RofecoxibRofecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational, Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
SalsalateSalsalate may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
SemapimodSemapimod may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
SeratrodastSeratrodast may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
SerrapeptaseSerrapeptase may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Neomycin.Approved, Investigational
SRT501SRT501 may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
SuccinylcholineNeomycin may increase the respiratory depressant activities of Succinylcholine.Approved
SulbactamThe serum concentration of Neomycin can be decreased when it is combined with Sulbactam.Approved
SulbenicillinThe serum concentration of Neomycin can be decreased when it is combined with Sulbenicillin.Experimental
SulfasalazineSulfasalazine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
SultamicillinThe serum concentration of Neomycin can be decreased when it is combined with Sultamicillin.Investigational
SuprofenSuprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
TalampicillinThe serum concentration of Neomycin can be decreased when it is combined with Talampicillin.Experimental
TarenflurbilTarenflurbil may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
TazobactamThe serum concentration of Neomycin can be decreased when it is combined with Tazobactam.Approved
Technetium Tc-99m etidronateNeomycin may increase the hypocalcemic activities of Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateNeomycin may increase the hypocalcemic activities of Technetium Tc-99m medronate.Approved
TenidapTenidap may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
Tenofovir disoproxilThe serum concentration of Neomycin can be increased when it is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Neomycin which could result in a higher serum level.Vet Approved
TeriflunomideTeriflunomide may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
TicarcillinThe serum concentration of Neomycin can be decreased when it is combined with Ticarcillin.Approved, Vet Approved
Tiludronic acidNeomycin may increase the hypocalcemic activities of Tiludronic acid.Approved, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
TioclomarolNeomycin may increase the anticoagulant activities of Tioclomarol.Experimental
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
TolmetinTolmetin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Neomycin.Approved
TranilastTranilast may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational
TribenosideTribenoside may decrease the excretion rate of Neomycin which could result in a higher serum level.Experimental
TriptolideTriptolide may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational
TubocurarineNeomycin may increase the respiratory depressant activities of Tubocurarine.Approved
ValdecoxibValdecoxib may decrease the excretion rate of Neomycin which could result in a higher serum level.Investigational, Withdrawn
VancomycinVancomycin may increase the nephrotoxic activities of Neomycin.Approved
VecuroniumNeomycin may increase the respiratory depressant activities of Vecuronium.Approved
WarfarinNeomycin may increase the anticoagulant activities of Warfarin.Approved
ZaltoprofenZaltoprofen may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved
ZileutonZileuton may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Zoledronic acidNeomycin may increase the hypocalcemic activities of Zoledronic acid.Approved
ZomepiracZomepirac may decrease the excretion rate of Neomycin which could result in a higher serum level.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Jaehoon Yu, Jongkook Lee, Miyun Kwon, Ae Pae, Hun Koh, "Heterodimeric conjugates of neomycin-oxazolidinone, their preparation and their use." U.S. Patent US20050222055, issued October 06, 2005.

US20050222055
General References
Not Available
External Links
KEGG Compound
C00384
PubChem Substance
46505525
ChEBI
7507
ChEMBL
CHEMBL449118
Therapeutic Targets Database
DAP000036
PharmGKB
PA450608
HET
CNY
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Neomycin
ATC Codes
J01GB05 — NeomycinA07AA51 — Neomycin, combinationsS01AA03 — NeomycinD06AX04 — NeomycinB05CA09 — NeomycinS03AA01 — NeomycinA07AA01 — NeomycinR02AB01 — NeomycinS02AA07 — NeomycinA01AB08 — Neomycin
AHFS Codes
  • 08:12.02 — Aminoglycosides
  • 84:06.00 — Anti-inflammatory Agents
  • 52:08.00 — Anti-inflammatory Agents
  • 52:04.04 — Antibacterials
  • 84:04.04 — Antibiotics
  • 52:08.08 — Corticosteroids
  • 40:36.00 — Irrigating Solutions
  • 84:28.00 — Keratolytic Agents
MSDS
Download (72.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Enrolling by InvitationBasic ScienceDietary Modifications / Nutrition1
0RecruitingSupportive CareDiverticulitis / Inflammatory Bowel Diseases (IBD) / Neoplasms, Colorectal / Surgical Site Infections1
0RecruitingTreatmentOsteomyelitis1
1CompletedNot AvailableNeoplasms1
1CompletedTreatmentPlasma Cell Myeloma1
1CompletedTreatmentSystemic Infections1
1RecruitingTreatmentRetinoblastoma1
1RecruitingTreatmentMinor burns1
2Active Not RecruitingTreatmentIntestinal Colonization With Multidrug-resistant Bacteria1
2Not Yet RecruitingPreventionLeak, Anastomotic / Rectal Carcinoma1
2RecruitingTreatmentAppendicitis1
2RecruitingTreatmentBacteremia / Chronic Lung Disease of Prematurity / Chronic Lung Diseases / Ileal perforation / Intraventricular Hemorrhage / Necrotizing Enterocolitis / Periventricular Leukomalacia / Retinopathy of Prematurity1
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentInfection NOS / Sepsis / Severe Sepsis / Shock, Septic1
2RecruitingTreatmentPre-Diabetic1
2Unknown StatusTreatmentPediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections1
2, 3Not Yet RecruitingTreatmentSocial Stress1
2, 3Unknown StatusPreventionBacteremia / Bacteremia Associated With Intravascular Line / Ventilator-associated Bacterial Pneumonia1
3CompletedTreatmentCommunity Acquired Infections / Infections, Gram-Positive Bacterial / Pneumonia, Pneumococcal1
3CompletedTreatmentPeriodontitis1
3CompletedTreatmentSinusitis1
3RecruitingPreventionCritical Illness / Sepsis / Shock, Septic / Ventilator-associated Bacterial Pneumonia1
3RecruitingTreatmentAcute Otitis Externa1
3RecruitingTreatmentUrinary Bladder, Overactive1
3TerminatedTreatmentBladder Cancers1
3TerminatedTreatmentSinusitis1
3Unknown StatusTreatmentAcute / Conjunctivitis, Bacterial1
3Unknown StatusTreatmentHordeolum1
3Unknown StatusTreatmentPneumonia1
4CompletedPreventionPostoperative Infections1
4CompletedTreatmentAllergies1
4CompletedTreatmentFunctional Dyspepsia / Helicobacter Pylori / Peptic Ulcers1
4CompletedTreatmentHelicobacter Pylori Treatment Failure1
4CompletedTreatmentIndigestion / Peptic Ulcers1
4CompletedTreatmentPostoperative Infections1
4CompletedTreatmentPyelonephritis1
4CompletedTreatmentVertebral Osteomyelitis1
4Not Yet RecruitingPreventionAntibiotic Prophylaxis / Tuberculosis, Pulmonary1
4Not Yet RecruitingTreatmentAcute Coronary Syndromes (ACS) / Non-valvular Atrial Fibrillation (NVAF)1
4Not Yet RecruitingTreatmentCystitis / Cystitis;Puerperium / Pyelonephritis1
4RecruitingPreventionAntibiotic Allergy / Antibiotic Side Effect / Eyelid Diseases / Eyelid; Wound / Infection, Postoperative Wound / Skin Cancer Face / Surgical Incision / Surgical Site Infections / Surgical Wound, Recent1
4RecruitingPreventionPostoperative Infections1
4RecruitingTreatmentBacterial Vaginosis (BV) / Candidiasis infection1
4WithdrawnPreventionComplications; Breast Prosthesis, Infection or Inflammation1
Not AvailableCompletedNot AvailableAcute Cholecystitits1
Not AvailableCompletedNot AvailableDiverticulitis1
Not AvailableCompletedNot AvailablePatients Colonized by Klebsiella Pneumoniae1
Not AvailableCompletedNot AvailablePenicillin Allergy1
Not AvailableCompletedDiagnosticMinor burns1
Not AvailableCompletedOtherFlu caused by Influenza1
Not AvailableCompletedPreventionAnal Fistulas1
Not AvailableCompletedPreventionBiliary Atresia1
Not AvailableCompletedPreventionInfection NOS1
Not AvailableCompletedTreatmentAggressive Periodontitis, Generalized1
Not AvailableCompletedTreatmentBMI >30 kg/m2 / Diabetes1
Not AvailableCompletedTreatmentConstipation-Predominant Irritable Bowel Syndrome1
Not AvailableCompletedTreatmentCorneal Diseases1
Not AvailableCompletedTreatmentDiverticulitis, Colonic1
Not AvailableCompletedTreatmentHospital Acquired Infections / Respiratory Tract Diseases1
Not AvailableCompletedTreatmentNasal Carriers of Staphylococcus Aureus1
Not AvailableCompletedTreatmentNeutropenia, Febrile1
Not AvailableCompletedTreatmentSnoring / Strep Throat1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableEnrolling by InvitationTreatmentAcute Appendicitis1
Not AvailableRecruitingNot AvailableMyelodysplastic Syndrome1
Not AvailableRecruitingBasic ScienceErythema Chronicum Migrans1
Not AvailableRecruitingPreventionAsymptomatic Bacteriuria / Pyelonephritis1
Not AvailableRecruitingPreventionGeneral Surgery / Infection NOS1
Not AvailableRecruitingTreatmentLiver Cirrhosis / Small Intestinal Bacterial Overgrowth1
Not AvailableTerminatedTreatmentBacterial Keratitis / Fungal Keratitis1
Not AvailableUnknown StatusNot AvailableAsymptomatic Infections / Bacteriuria / Transplantation Infection / Urinary Tract Infections (UTIs)1
Not AvailableUnknown StatusPreventionInfection NOS1
Not AvailableUnknown StatusTreatmentHepatic Encephalopathy / Liver Cirrhosis / Portal Hypertension1
Not AvailableWithdrawnNot AvailableCystic Fibrosis (CF)1
Not AvailableWithdrawnTreatmentMinor burns1

Pharmacoeconomics

Manufacturers
  • X gen pharmaceuticals inc
  • Pharmacia and upjohn co
  • Pfizer laboratories div pfizer inc
  • Bristol myers squibb co
  • Lannett co inc
  • Eli lilly and co
  • Oman pharmaceutical products co llc
  • Roxane laboratories inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
Kit
PowderTopical
OintmentTopical3.5 mg/g
CreamTopical5 mg/.9g
SuspensionTopical
SuspensionAuricular (otic)
Suspension / dropsAuricular (otic)
KitTopical
OintmentOphthalmic; Topical
OintmentTopical
StickTopical
Solution / dropsOphthalmic
CreamTopical
SolutionOral125 mg
TabletOral500 mg
OintmentTopical.5 %
SuspensionAuricular (otic); Ophthalmic
SolutionOral87.5 mg/5mL
LotionTopical
Suspension / dropsOphthalmic
LiquidAuricular (otic); Ophthalmic
IrrigantIrrigation
SolutionIrrigation
SolutionAuricular (otic)
Solution / dropsAuricular (otic)
OintmentOphthalmic
TabletOral350 mg/1
TabletOral500 mg/1
SuspensionOphthalmic
SolutionOphthalmic
SolutionAuricular (otic); Ophthalmic
SolutionUrethral
LiquidOphthalmic
GelTopical
Solution / dropsAuricular (otic); Ophthalmic
OintmentTopical3.5 mg/57g
OintmentRectal
SuppositoryRectal
Prices
Unit descriptionCostUnit
Neomycin Sulfate 500 mg tablet1.39USD tablet
Neomycin 500 mg tablet1.25USD tablet
Neomycin sulfate powder0.84USD g
Neo-fradin 125 mg/5 ml soln0.12USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)6 mg/mL (as sulfate form)Not Available
logP-7.8Not Available
Predicted Properties
Not Available
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8617
Blood Brain Barrier-0.9659
Caco-2 permeable-0.7502
P-glycoprotein substrateNon-substrate0.5164
P-glycoprotein inhibitor INon-inhibitor0.8023
P-glycoprotein inhibitor IINon-inhibitor0.8764
Renal organic cation transporterNon-inhibitor0.7886
CYP450 2C9 substrateNon-substrate0.8231
CYP450 2D6 substrateNon-substrate0.8041
CYP450 3A4 substrateNon-substrate0.6473
CYP450 1A2 substrateNon-inhibitor0.9157
CYP450 2C9 inhibitorNon-inhibitor0.9147
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9034
CYP450 3A4 inhibitorNon-inhibitor0.9471
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8446
Ames testNon AMES toxic0.6934
CarcinogenicityNon-carcinogens0.9505
BiodegradationNot ready biodegradable0.8587
Rat acute toxicity1.4850 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9728
hERG inhibition (predictor II)Non-inhibitor0.81
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Trna binding
Specific Function
With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
Gene Name
rpsL
Uniprot ID
P0A7S3
Uniprot Name
30S ribosomal protein S12
Molecular Weight
13736.995 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Gill AE, Amyes SG: The contribution of a novel ribosomal S12 mutation to aminoglycoside resistance of Escherichia coli mutants. J Chemother. 2004 Aug;16(4):347-9. [PubMed:15332709]
  4. Eisenstein BI, Beachey EH, Ofek I: Influence of sublethal concentrations of antibiotics on the expression of the mannose-specific ligand of Escherichia coli. Infect Immun. 1980 Apr;28(1):154-9. [PubMed:6103875]
2. 16S rRNA
Kind
Nucleotide
Organism
Enteric bacteria and other eubacteria
Pharmacological action
Yes
Actions
Inhibitor
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Roy U, Nair D: Biodiversity of organotin resistant Pseudomonas from west coast of India. Ecotoxicology. 2007 Mar;16(2):253-61. Epub 2006 Nov 28. [PubMed:17131180]
  4. Wachino J, Shibayama K, Kurokawa H, Kimura K, Yamane K, Suzuki S, Shibata N, Ike Y, Arakawa Y: Novel plasmid-mediated 16S rRNA m1A1408 methyltransferase, NpmA, found in a clinically isolated Escherichia coli strain resistant to structurally diverse aminoglycosides. Antimicrob Agents Chemother. 2007 Dec;51(12):4401-9. Epub 2007 Sep 17. [PubMed:17875999]
  5. Brown JM, Cowley KD, Manninen KI, McNeil MM: Phenotypic and molecular epidemiologic evaluation of a Nocardia farcinica mastitis epizootic. Vet Microbiol. 2007 Nov 15;125(1-2):66-72. Epub 2007 May 6. [PubMed:17553640]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
Senses changes in the extracellular concentration of calcium ions. The activity of this receptor is mediated by a G-protein that activates a phosphatidylinositol-calcium second messenger system.
Gene Name
CASR
Uniprot ID
P41180
Uniprot Name
Extracellular calcium-sensing receptor
Molecular Weight
120672.385 Da
References
  1. Molostvov G, James S, Fletcher S, Bennett J, Lehnert H, Bland R, Zehnder D: Extracellular calcium-sensing receptor is functionally expressed in human artery. Am J Physiol Renal Physiol. 2007 Sep;293(3):F946-55. Epub 2007 May 30. [PubMed:17537980]

Drug created on June 13, 2005 07:24 / Updated on October 21, 2017 09:34